Letter by Tsuda Regarding Article, “A Novel α-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
I read with great interest the article by Dr Aubdool and colleagues1 dealing with the effects of a novel potent and long-lasting acetylated α-calcitonin gene-related peptide (α-CGRP) analogue on cardiovascular damages in 2 distinct murine models of hypertension and heart failure in vivo. The results of their study demonstrated that the angiotensin II–induced hypertension was attenuated by cotreatment of α-CGRP analogue. The α-CGRP analogue protected against vascular, renal, and cardiac dysfunction, characterized by reduced hypertrophy and biomarkers of fibrosis, remodeling, inflammation, and oxidative stress. In addition, the authors …